Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

20,959 total articles

Bioventus Reports First Quarter Financial Results

Bioventus Reports First Quarter Financial Results

Bioventus Inc. reported solid financial results for Q1 2026, with revenue increasing 7% to $132.1 million driven by growth across its Pain Treatments, Surgical Solutions, and Restorative Therapies segments. GAAP earnings improved to $0.04 per diluted share from a prior year loss, and non-GAAP earnings nearly doubled to $0.15 per diluted share. The …

Cronos Expands Pre-Roll Portfolio with Spinach STIX®

Cronos Expands Pre-Roll Portfolio with Spinach STIX®

Cronos Group Inc., a global cannabis company, announced the expanded availability of its Spinach STIX®, a cylindrical-style pre-roll, across multiple Canadian provinces. This expansion targets the rising consumer demand for innovative and portable cannabis pre-roll formats in the Canadian market, which accounts for over a third of national retail c…

Dragonfly Energy Selected for Additional Nevada Tech Hub Funding to Advance Battery R&D and Cell Development

Dragonfly Energy Selected for Additional Nevada Tech Hub Funding to Advance Battery R&D and Cell Development

Dragonfly Energy Holdings Corp. has been awarded a second round of funding from the Nevada Tech Hub, amounting to $527,000, to expand its in-house cylindrical lithium battery cell prototyping and advanced testing capabilities. This investment aims to accelerate research and development, enhance validation processes, and strengthen integration betwe…

BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil

BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil

BridgeBio Pharma announced that the Brazilian regulatory agency ANVISA has approved acoramidis, marketed as Beyonttra, for treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM). This approval follows positive Phase 3 trial results demonstrating significant reductions in cardiovascular events and hospitalizations, marking the first near-co…

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

Medicus Pharma Ltd. announced expanded pre-specified data from its Phase 2 SKNJCT-003 study showing a positive, dose-dependent response for its Doxorubicin Microneedle Array (D-MNA) treatment of nodular basal cell carcinoma, strengthening the drug's clinical profile and regulatory positioning ahead of FDA discussions. The 200µg dose cohort showed t…

REalloys (NASDAQ: ALOY) Receives Department of War Memorandum on Securing Domestic Heavy Rare Earth Supply Ahead of 2027 Deadline

REalloys (NASDAQ: ALOY) Receives Department of War Memorandum on Securing Domestic Heavy Rare Earth Supply Ahead of 2027 Deadline

REalloys Inc. has received a memorandum from the Department of War emphasizing the urgent national security need to secure domestic heavy rare earth elements (HREE), particularly Dysprosium and Terbium, ahead of a 2027 ban on Chinese-origin rare earth materials. REalloys is developing the largest heavy rare earth metallization facility outside Chin…

Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update

Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update

Lifecore Biomedical announced its financial results for Q1 2026, showing a 34% decline in revenue to $23.2 million and a net loss of $15.0 million. Despite top-line challenges, the company implemented cost containment strategies reducing operating expenses by 52%, launched a new ERP system to improve efficiencies, signed three new commercial site t…

TransAlta Reports First Quarter Results and Reaffirms Annual Guidance

TransAlta Reports First Quarter Results and Reaffirms Annual Guidance

TransAlta reported first quarter 2026 results showing strong operational availability and cash flow despite softer Alberta power prices and lower production. The company reaffirmed its 2026 outlook, announced leadership changes, strategic moves in data center development, acquisition of Far North assets, and increased its dividend by 8%. However, a…

Royalty Pharma reports first quarter 2026 results

Royalty Pharma reports first quarter 2026 results

Royalty Pharma plc reported 10% growth in Portfolio Receipts to $925 million and 13% growth in Royalty Receipts to $887 million in Q1 2026. The company announced up to $1.25 billion in royalty transactions including R&D co-funding deals with Johnson & Johnson and Teva. Positive clinical developments in its portfolio products and strengthened capabi…

Perma-Fix Reports First Quarter 2026 Results and Strategic Outlook

Perma-Fix Reports First Quarter 2026 Results and Strategic Outlook

Perma-Fix Environmental Services, Inc. reported first quarter 2026 financial results reflecting a transitional period with reduced revenues and operating losses due to seasonal softness and investments preparing for increased activity, especially related to Hanford waste projects, Nuclear Services mobilization, and PFAS technology expansion. Despit…

Astec Reports First Quarter 2026 Results

Astec Reports First Quarter 2026 Results

Astec Industries, Inc. announced first quarter 2026 financial results with a 20.3% increase in net sales reaching $396.3 million, driven primarily by a 70.6% rise in Materials Solutions net sales. Despite the sales growth, net income declined sharply to $1.3 million from $14.3 million the prior year, affected by timing and mix shifts in Infrastruct…

J & J Snack Foods Reports Fiscal 2026 Second Quarter Results

J & J Snack Foods Reports Fiscal 2026 Second Quarter Results

J & J Snack Foods Corp. reported its fiscal 2026 second quarter results with net sales decreasing by 3.2% year-over-year to $344.8 million primarily due to expected declines in the bakery segment. Despite lower sales, gross profit improved by 3.8% and gross margin expanded. Operating income decreased substantially due to non-recurring plant closure…

Advantage Solutions Reports First Quarter 2026 Results

Advantage Solutions Reports First Quarter 2026 Results

Advantage Solutions Inc. delivered a solid first quarter with revenues increasing 5.8% to $869.6 million and Adjusted EBITDA growing 16.4% to $67.7 million, driven primarily by strong performance in Experiential Services and improved profitability in Retailer Services. Despite a net loss widening to $71.8 million due to higher expenses and non-cash…

Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET

Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET

Aquestive Therapeutics will report its financial results for the first quarter ending March 31, 2026, on May 13, followed by an investor call on May 14. The company highlighted ongoing development programs including its Anaphylm™ sublingual film and AQST-108 topical gel, advancing treatments for severe allergic reactions and dermatological conditio…

Hyperion DeFi Announces Pricing of Public Offering of Common Stock

Hyperion DeFi Announces Pricing of Public Offering of Common Stock

Hyperion DeFi, Inc., a Nasdaq-listed decentralized finance company, announced the pricing of a public offering of nearly 2.78 million common shares at $3.60 per share, expected to raise approximately $10 million. The proceeds are to be used to enhance its treasury strategy by acquiring additional HYPE tokens and for general corporate purposes. The …